alexa Abstract | Beta-lactamases in P. aeruginosa: A Threat to Clinical Therapeutics

Current Pediatric Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article Open Access


Pseudomonas aeruginosa is the third most common pathogen responsible for nosocomial infections. The prevalence of multiple drug resistant Pseudomonas aeruginosa isolates harboring beta lactamases have been increasing. The present study is designed to determine the occurrence of various beta lactamases in Pseudomonas aeruginosa. A total of 237 clinical isolates of P. aeruginosa were tested for the presence of AmpC beta-lactamase, Extended Spectrum Beta-Lactamase (ESBL) and Metallo Beta-Lactamase (MBL) enzyme. Detection of ESBL was done by the combined disk diffusion method as per Clinical and Laboratory Standards Institute (CLSI) guidelines whereas MBL were detected by the Imipenem EDTA disk potentiation test and AmpC beta-lactamase was detected by disk antagonism test and modified three-dimensional method respectively. A total of 82 (34.60%) isolates were positive for AmpC beta-lactamase, 52 (21.94%) ESBL and 40 (16.87%) were positive for MBL. Coproduction of AmpC with extended spectrum beta-lactamase and metallo beta-lactamase was reported in 20 (08.44%) and 24 (10.12%) isolates, respectively. All the three beta lactamases co-production was found to be in 7 (2.95%) isolates. The study emphasizes early detection of these multidrug resistant P. aeruginosa producing beta-lactamase enzymes of diverse mechanisms. Thus proper antibiotic policy and measures to restrict the indiscriminate use of antibiotics should be taken to minimize the emergence of these multiple beta-lactamase producing pathogens to avoid therapeutic failures and nosocomial outbreaks.

To read the full article Peer-reviewed Article PDF image

Author(s): Supriya Tankhiwale


Beta lactamase, P. aeruginosa, Amp C, MBL, ESBL, Pediatrics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version